Does it matter where you are treated? TJBCM publishes five-year review of NHS brain cancer services

October 14, 2026

Five-year review charts major progress towards more equitable NHS brain tumour care as Centres of Excellence more than double

One of the most comprehensive studies of NHS services in any cancer is published today. Since the programme’s inception in 2021, the number of Tessa Jowell Centre of Excellence has grown from 9 to 20, meaning more patients can now access a high standard of treatment and care. But significant inequalities remain in access to clinical trials and rehabilitation, while delays in diagnostic testing are growing.

15 October 2026: Care for patients with a brain tumour across the UK has become more consistent and equitable over the past five years, according to a landmark review from the Tessa Jowell Brain Cancer Mission, launched today.

The State of the Nation report, Does it matter where you are treated?, draws on five years of evidence from 25 NHS neuro-oncology centres caring for more than 90% of UK brain tumour patients. While it charts considerable progress, the report also highlights where these improvements are not reaching every patient equally, in a cancer where outcomes remain poor and new treatment options are urgently needed.

The findings come from the Tessa Jowell Centre of Excellence programme, set up five years ago to build the first national picture of brain tumour services and use that evidence to make care more equitable. Every participating centre has since reached a core standard of multidisciplinary care, alongside significant advances in precision medicine and specialist support. Participating NHS teams have delivered 163 service improvement projects, while the number of Centres of Excellence has grown from 9 in 2021 to 20 today – demonstrating how transparent measurement, shared standards and targeted service development can translate into more equitable care, even in a highly pressured system.

Drawing on data collected by more than 500 NHS staff, feedback from 3,000 people with lived experience via The Brain Tumour Charity, and independent review by more than 30 clinical experts, the report finds:

  • Specialist treatment is more consistent, despite growing pressure on services. Every centre now provides specialist multidisciplinary treatment in line with international standards. While the vast majority of patients continue to receive timely treatment, there are signs of growing pressure across the wider pathway. For example, urgent MRI reporting now takes five days (40%) longer than in 2021, and the proportion of centres achieving a molecular diagnosis within two weeks has halved to 25% – both risking delays to treatment.
  • Precision medicine has expanded, but this innovation is only reaching some patients. The proportion of centres submitting samples for whole genome sequencing has risen from 21% to 88%, but access within some centres remains restricted to relatively few patients. Meanwhile, 96% of centres report barriers to opening clinical trials, limiting access to novel therapies and contributing to significant variation in the opportunities available to patients across the UK.
  • Rehabilitation has improved substantially, but important gaps remain. Centres across the UK have strengthened rehabilitation services, with 20 of 25 actively developing provision. Yet only 3 of 25 centres have full occupational therapy, physiotherapy and speech and language therapy staffing across inpatient and outpatient services, and some lack dedicated neurology or neuropsychology provision.

Dr Nicky Huskens, CEO of the Tessa Jowell Brain Cancer Mission and senior author of the study, said:

“Five years ago, nine centres met our standards for excellence. Today, 20 do. That represents real progress towards making excellent brain tumour care more equitable across the UK.

We should not confuse progress in services with having solved the enormous challenges facing patients. Outcomes for many people with brain tumours remain devastatingly poor, and the report clearly highlights areas where further improvement is needed.

What these five years do show clearly is that measuring variation, agreeing what excellence looks like and supporting teams to act on the evidence can truly change services at national scale. Our task now is to build on that progress and tackle the areas where patients are still being left behind.”

Sam Suriakumar, from London, was initially diagnosed in 2020 with a glioma, after having a seizure on the London Underground on his way home from work. The father of two underwent multiple rounds of treatment at a Tessa Jowell Centre of Excellence and has since raised money and awareness for charities including the Tessa Jowell Foundation and Brain Tumour Research.

Reflecting on the importance of wrap-around care and rehabilitation, Sam said:

“The right emotional and practical support can give people the confidence to keep living alongside their diagnosis, rather than allowing the diagnosis to become their whole life. These things cannot always be measured in a laboratory or seen on a scan, but their impact can be profound. That is why the work of the Tessa Jowell Brain Cancer Mission means so much to me. Its ambition for excellence in brain tumour care recognises something I have come to believe deeply: that world-class treatment and truly human care must go hand in hand.”

Sam and his family

From evidence to national action

Evidence from the programme has helped to drive change in individual hospitals, but the most persistent challenges will need coordinated action from NHS leaders, governments, commissioners and the wider brain tumour community. The report therefore  sets out 15 recommendations to strengthen specialist workforce and diagnostic capacity, achieve equitable access to genomic testing and clinical trials, and ensure every patient receives comprehensive, wrap-around care.

This comes at a key moment for rare cancer policy: the 2026 National Cancer Plan and Rare Cancers Act both include commitments to improve access to specialist care, genomic testing and clinical trials for rare cancer patients. The programme’s nationwide dataset offers a way to track how those commitments translate into better care.

Professor Richard Gilbertson, Chair of the TJBCM, Master of Gonville and Caius College, Cambridge and the Li Ka Shing Chair of Oncology at the University of Cambridge, said:

” Dame Tessa Jowell’s vision was that every person diagnosed with a brain tumour should have access to the very best treatment, care and research, wherever they are diagnosed. Five years on, this report shows how far we have come towards making that vision a reality. It is a testament to the collective work of hundreds of clinicians, researchers, patients, and our funders in the charity sector and government. There is much more to do, but this collaboration gives me confidence that we can overcome the challenges identified, and make the most of the opportunities in the National Cancer Plan.”

What improvement looks like in practice: six new Tessa Jowell Centres of Excellence

Sussex neuro-oncology team

The publication of the report coincides with the recognition of six NHS neuro-oncology teams as new Tessa Jowell Centres of Excellence, bringing the number to 20 centres covering two thirds of the UK.

Dr Cressida Lorimer and Dr Ed Chandy, both clinical oncologists at the newly designated Tessa Jowell Centre of Excellence at Royal Sussex County Hospital said

“Neuro-oncology depends on bringing together many different services around each patient. We are particularly pleased that the review recognised the strength of our multidisciplinary working, our nurse-led care, neurology,  imaging services, and the breadth of support we provide for patients with low-grade glioma. Most importantly, we see this as recognition of a service that continues to evolve. Over recent years we have made substantial developments in surgery, genomics, nursing, and rehabilitation, while strengthening our links with local services. 

One recent development of which we are particularly proud is the establishment of a pathway for the collection and storage of tumour tissue for whole genome sequencing. This initiative has strengthened our ability to deliver precision medicine, providing patients with access to advanced molecular diagnostics and opening up opportunities for recruitment into clinical trials that may not previously have been available.”

The designations follow independent assessment across treatment, care, research and service improvement. Together, the centres provide practical examples of how evidence can lead to better services – and how successful approaches can be shared across the NHS.

The full State of the Nation report is available below: